Skip to content
An Initiative of AVAC In partnership with Access Bridge
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 321 - 330 of 428

Selected Filters:
7 July 2022

Health Care Providers’ Attitudes toward and Experiences Delivering Oral PrEP to Adolescent Girls and Young Women in Kenya, South Africa, and Zimbabwe

This article describes the results of a cross-sectional qualitative study, interviewing providers at public, private, and nongovernmental health facilities in Kenya, South Africa, and Zimbabwe offering PrEP to explore providers’ attitudes toward and experiences delivering PrEP to AGYW.

Research, Service Delivery

External Link
7 July 2022

Health care providers’ attitudes toward and experiences delivering oral PrEP to adolescent girls and young women: Kenya technical brief

This technical brief describes the results of a cross-sectional qualitative study, interviewing providers at public, private, and nongovernmental health facilities in Kenya offering PrEP to explore providers’ attitudes toward and experiences delivering PrEP to AGYW.

Research, Service Delivery

Document
7 July 2022

Health care providers’ attitudes toward and experiences delivering oral PrEP to adolescent girls and young women: Zimbabwe technical brief

This technical brief describes the results of a cross-sectional qualitative study, interviewing providers at public, private, and nongovernmental health facilities in Zimbabwe offering PrEP to explore providers’ attitudes toward and experiences delivering PrEP to AGYW.

Research, Service Delivery

Document
7 July 2022

DISCOVER study for HIV pre-exposure prophylaxis (PrEP): F/TAF has a more rapid onset and longer sustained duration of HIV protection compared with F/TDF

In the DISCOVER study, F/TAF oral PrEP (Descovy) was statistically noninferior to F/TDF oral PrEP (Truvada). However, there were numerically 53% fewer HIV infections in the F/TAF arm vs. F/TDF . This study explores HIV risk, STIs, adherence, and pharmacokinetic data to evaluate this imbalance.

Research

External Link
7 July 2022

DISCOVER Trial Factsheet

This factsheet provides details on the DISCOVER trial to assess whether F/TAF (trade name Descovy) is as safe and effective as an oral daily HIV pre-exposure prophylaxis (PrEP) product.

Community/Advocacy, Research

External Link
7 July 2022

Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness

A vaginal ring containing dapivirine is effective for HIV prevention as pre-exposure prophylaxis (PrEP). The authors of this article evaluated the potential epidemiological impact and cost-effectiveness of dapivirine vaginal ring PrEP among 22- to 45-year-old women in KwaZulu-Natal, South Africa.

Research, Service Delivery

External Link
7 July 2022

MTN-023/IPM 030 “iMatter”

Microbicide Trials Network-023/International Partnership for Microbicides 030 was a Phase 2a trial to assess safety of the dapivirine vaginal ring in HIV-uninfected adolescent females

Research, Service Delivery

External Link
7 July 2022

Safety, Adherence and HIV-1 Seroconversion in DREAM – An Open-label Dapivirine Vaginal Ring Trial

The Ring Study, a phase 3 trial in 1959 sexually active women (randomised 2:1), showed a favourable safety profile and a 31% HIV-1 infection risk reduction for a vaginal ring containing 25 mg of dapivirine, compared with a placebo ring. This article features a report on the DREAM study, which aimed to evaluate safety, adherence,…

Research

Document
7 July 2022

Final Results of Open-label Study of IPM’s Dapivirine Vaginal Ring Show Increased Use and Suggest Lower Infection Rates Compared to Earlier Phase III Study

This letter from the International Partnership for Microbicides outlines the results of an open-label study on the Dapivirine Vaginal Ring

Research

External Link
7 July 2022

Results of open-label study of a vaginal ring for HIV prevention suggest women are interested in and willing to use it

This article from the Microbicide Trials Network shares the results of an open-label study of a vaginal ring for HIV prevention

Community/Advocacy, Demand Creation/Marketing, Research

External Link